CION Ameerpet
Immunotherapy · Understanding Immunotherapy & the Decision
Is Immunotherapy Only for Stage 4 Cancer — What the Stage Actually Decides
No — immunotherapy is no longer only for Stage 4 cancer. It's now used earlier too, as adjuvant therapy after surgery or neoadjuvant therapy before it, in cancers where trials show it lowers recurrence risk. But stage is only one factor: cancer type, biomarkers and specific approvals decide who qualifies, and most patients are not candidates.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist (MBBS Gold Medal · DNB · DM Medical Oncology, Gold Medal) · Last reviewed August 2026
- Not just a last resort — Adjuvant and neoadjuvant immunotherapy is now approved for several early and locally advanced cancers, not only Stage 4 disease.
- Stage is one factor, not the only one — Cancer type, biomarker results (like PD-L1 or MSI status) and specific drug approvals matter as much as stage.
- Most patients are still not candidates — Immunotherapy fits a defined subset of cancers and patients; it is not a universal option at any stage.
- A decision, not a default — Your oncology team weighs your specific diagnosis against what's actually approved and evidenced before recommending it.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The short answer
Is Immunotherapy Only Used for Advanced or Metastatic Cancer?
No. Immunotherapy began as a treatment for metastatic (Stage 4) disease, but it is now also approved as adjuvant treatment after surgery and neoadjuvant treatment before surgery, in several early and locally advanced cancers — including certain melanoma, non-small-cell lung, kidney, bladder and triple-negative breast cancer cases. It is also still not approved, or not appropriate, for many other cancer types and stages, so stage alone never decides the answer for an individual patient.
This page explains the framework your oncology team actually uses — it is not a substitute for that assessment, and it does not recommend immunotherapy for any specific person.
A framework, not a recommendation
What Actually Decides If Immunotherapy Is an Option for You?
Stage is one input among several. Your oncology team weighs all of the following together — and for some patients, the honest answer is that immunotherapy is not the right fit at any stage.
1
Cancer type and subtype
Immunotherapy is approved for a defined list of cancer types and subtypes. If your cancer type isn't on that list, stage doesn't change the answer.
2
Stage and disease setting
Early, locally advanced and metastatic disease each carry their own approved uses — adjuvant, neoadjuvant, or ongoing systemic treatment — and not every setting has one.
3
Biomarker results
Tests such as PD-L1 expression, MSI/dMMR status or tumour mutational burden, where relevant to your cancer type, often decide eligibility more than stage does.
4
Approved indication in India
A specific drug has to be approved for your specific cancer type and stage — an approval for metastatic disease doesn't automatically extend to earlier stages, or the reverse.
5
Overall health and history
Autoimmune conditions, organ transplants, long-term steroid use or a prior severe immune reaction can rule immunotherapy out regardless of how well it might otherwise fit.
6
Alternatives, including no immunotherapy at all
Surgery alone, targeted therapy, chemotherapy or active surveillance can be the more evidenced choice for a given stage and cancer type — your team should lay this option out as clearly as immunotherapy itself.
Did you know?
Adjuvant immunotherapy after surgery for high-risk, node-positive melanoma was approved years before many patients realise the treatment existed outside Stage 4 disease — the "last resort" reputation has outlived the current evidence.
Said plainly, before anything else
Who Is Not a Candidate for Immunotherapy, Regardless of Stage?
Most cancer patients, at any stage, are not candidates for immunotherapy. It is intended for a defined subset of cancers and patients — not a general-purpose option that becomes available once a cancer reaches a certain stage.
- Your cancer type has no approved immunotherapy indication at your stage or disease setting
- Biomarker testing (PD-L1, MSI/dMMR or similar, where relevant) does not support its use in your case
- You have an active autoimmune condition that immunotherapy could seriously worsen
- You are on long-term steroids or immunosuppressant medication, such as after an organ transplant
- You have had a severe immune-related reaction to immunotherapy in the past
- Your overall health and organ function cannot safely support any systemic cancer treatment right now
None of these are judged from stage alone — they come from pathology reports, biomarker testing and a review of your medical history, done before any recommendation is made.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Want a Straight Answer on Your Own Stage and Cancer Type?
A medical oncologist can review your reports and tell you plainly whether immunotherapy is approved and appropriate for your specific situation — free, confidential, no commitment to start treatment.
A term worth understanding
What Is Adjuvant Immunotherapy?
Adjuvant immunotherapy is treatment given after the main treatment — usually surgery — once imaging and pathology show no visible cancer left in the body. Its goal is to lower the chance the cancer comes back, not to treat disease that can currently be seen or measured. It is typically offered to patients whose original cancer carried a meaningful risk of recurrence, based on stage, biomarkers and the specific cancer type's approved use.
Neoadjuvant immunotherapy is the reverse timing: it's given before the main treatment, usually surgery, while the tumour is still in place. The intent is to shrink the tumour, potentially make surgery easier or more complete, and let the immune system start acting on cancer cells the surgeon can later remove and examine for how well treatment worked.
Both are examples of immunotherapy being used for disease that is not Stage 4 — a use case that has grown steadily and that many newly-diagnosed patients simply haven't heard of yet.
Across the stage spectrum
Where Does Immunotherapy Actually Fit, by Disease Setting?
This shows typical patterns across cancer types where immunotherapy has an approved use — not every drug is approved for every row below, and your own cancer type may not appear on this table at all.
| Disease setting | Common term | Typical goal | Example use |
|---|---|---|---|
| Early stage, after surgery | Adjuvant | Lower the chance of recurrence | High-risk resected melanoma; select lung and kidney cancers |
| Locally advanced, before surgery | Neoadjuvant | Shrink the tumour and prime an immune response before removal | Select non-small-cell lung and bladder cancers |
| Metastatic (Stage 4) | First- or later-line systemic therapy | Control the spread of disease over time | The original, most established use across several cancer types |
| After an initial combination | Maintenance | Sustain a response already achieved | Continuing immunotherapy alone after a chemotherapy-immunotherapy combination |
Exact use depends on the specific drug's approved indication for your cancer type and stage — not every combination in this table applies to every cancer or every patient.
The question behind the question
Is Immunotherapy Ever Curative?
Oncologists are careful with the word "cure" when discussing immunotherapy. In some early-stage cases treated with adjuvant immunotherapy, or in a subset of advanced cancers with a strong and lasting response, the disease can become undetectable for years — a state usually described as durable remission or long-term disease control, because long-term follow-up is still maturing for many regimens. For most patients, especially with metastatic disease, the realistic goal your oncology team will describe is disease control, not cure.
This caution isn't pessimism — it reflects how oncology defines evidence. Calling a treatment curative requires years of follow-up data across large groups of patients, and immunotherapy, especially in its newer adjuvant and neoadjuvant uses, is still generating that data. Guideline bodies such as NCCN and ASCO update their recommendations as this follow-up matures, which is also why your oncologist's answer today may get more precise over time — not because anything told to you earlier was wrong.
It is fair to hope for a strong, lasting response. It is equally fair for your oncology team to stop short of promising one — that reflects the genuine, evolving state of the evidence, not reluctance to share good news.
If you are found eligible
What Happens Next If Your Oncology Team Confirms You're Eligible?
1
Biomarker and pathology confirmation
Your pathology and biomarker results are checked against the specific drug's approved indication for your cancer type and stage.
2
Multidisciplinary tumour board review
Your case is discussed by medical oncology alongside surgery, radiation and pathology colleagues where relevant, not decided by one specialist alone.
3
A plain conversation about goals and limits
Your oncologist explains what immunotherapy is intended to do in your specific case — reducing recurrence risk, controlling disease, or something else — and what it is not expected to do.
4
Day-care administration begins
Immunotherapy is delivered as day care at CION centres, on the cycle schedule your oncology team sets for your specific regimen.
5
Monitoring for immune-related side effects continues
Bloodwork and symptom checks continue through treatment, because the same immune activation that can help against cancer can also affect other organs.
You don't have to guess
Stage Is One Question — Let's Answer the Rest Together
A medical oncologist can review your specific cancer type, stage and biomarker results and tell you, plainly, whether immunotherapy is actually an option — and if not, what is.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Is Immunotherapy Only for Stage 4 Cancer? — Your Questions Answered
Is immunotherapy only used for Stage 4 cancer?
No. Immunotherapy began as a treatment for metastatic (Stage 4) disease, but it is now also approved as adjuvant treatment after surgery and neoadjuvant treatment before surgery in several early and locally advanced cancers, including certain melanoma, lung, kidney, bladder and triple-negative breast cancer cases. It is also still not approved, or not appropriate, for many other cancer types and stages, so stage alone never decides the answer for an individual patient.
What is adjuvant immunotherapy?
Adjuvant immunotherapy is treatment given after the main treatment — usually surgery — once imaging and pathology show no visible cancer left in the body. Its goal is to lower the chance the cancer comes back, not to treat disease that can be seen or measured. It is typically offered to patients whose original cancer carried a meaningful risk of recurrence, based on stage, biomarkers and the specific cancer type's approved use.
What is neoadjuvant immunotherapy, and how is it different?
Neoadjuvant immunotherapy is given before the main treatment, usually surgery, while the tumour is still in place. The intent is to shrink the tumour, make surgery easier or more complete, and let the immune system start acting on cancer cells the surgeon can later remove and examine. Adjuvant treatment, by contrast, is given after surgery, once no visible disease remains, mainly to reduce recurrence risk.
Is immunotherapy ever curative?
Oncologists are careful with the word "cure" when discussing immunotherapy. In some early-stage cases treated with adjuvant immunotherapy, or in a subset of advanced cancers with a strong and lasting response, the disease can become undetectable for years — a state usually described as durable remission or long-term disease control, because long-term follow-up is still maturing for many regimens. For most patients, especially with metastatic disease, the realistic goal your oncology team will describe is disease control, not cure.
Who is not a candidate for immunotherapy, regardless of stage?
Most cancer patients, at any stage, are not candidates for immunotherapy. It is not approved for every cancer type, and within an approved cancer type it is usually restricted to patients whose biomarker results — such as PD-L1 expression or MSI/dMMR status — support its use. Certain autoimmune conditions, long-term steroid or immunosuppressant use, a prior organ transplant, or a previous severe immune-related reaction can also rule it out. Your oncology team confirms eligibility with pathology and biomarker testing before recommending it.
Does earlier-stage immunotherapy carry the same side effects as Stage 4 treatment?
Broadly, yes — the same immune-related side effects (skin, gut, thyroid, lung and other organ reactions) can occur whether immunotherapy is used as adjuvant treatment after surgery, neoadjuvant treatment before it, or for metastatic disease, because the mechanism of action is the same. The duration of treatment and the underlying disease context differ, but the monitoring and escalation approach your oncology team follows for side effects does not change based on stage.
This page is general patient-education information, not a substitute for the written guidance your own oncology team gives you based on your specific pathology, biomarker results and treatment plan.